Physician profile
Alfonso Ramirez
NPI 1184600637
$2,451.29
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $915 · 2020: $516 · 2021: $692 · 2022: $329.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $806.84 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $421.12 | 2019-2021 | |
| Lilly USA, LLC | $338.89 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $173.39 | 2019 | |
| Novo Nordisk INC | $125.13 | 2021 | |
| Abbvie INC. | $122.39 | 2021-2022 | |
| Gilead Sciences, INC. | $120.55 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $117.47 | 2022 | |
| Pfizer INC. | $69.37 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $42.67 | 2020 | |
| Mylan Specialty L.P. | $32.45 | 2022 | |
| Allergan, INC. | $31.26 | 2019-2020 | |
| Radius Health, INC. | $19.80 | 2020 | |
| Amgen INC. | $15.36 | 2019 | |
| Glaxosmithkline, LLC. | $14.60 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alfonso Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.